金复康口服液治疗非小细胞肺癌的临床观察

Clinical Observation on Non - small Cell Lung Carcinoma Treated by Jinfukang Oral Solution

针对肺癌以气阴两虚证候为多数,研制了以益气养阴为主的中药制剂——金复康口服液,金复康组96例,治后CR1例,PR8例,NC52例,PR+NC为63.5％;金复康加化疗组52例,治后PR11例,NC26例,PR+NC为71.2％;单纯化疗组25例,PR4例,NC26例,PR+NC为60.0％,显示金复康及金复康加化疗组的疗效均较单纯化疗组为优。治疗后1年及2年生存率,金复康组分别为67.3％及67.3％;金复康加化疗组为66.7％及66.7％;单纯化疗组1年生存率为40.3％,无2年生存率。治疗后临床症状改善,体重增加及健康状况(KPS评分),金复康组及金复康加化疗组均优于单纯化疗组。金复康治后多项免疫指标及血象的改善均较治前显著提高,化疗组则有所降低,金复康加化疗组则无明显变化。

In view of the deficiencies of both Qi and Yin in most cases of this tumor, Jinfukang oral solution (JFK). a remedy mainly for benefiting Qi and nourishing -yin. was formulated. 96 cases were treated with one case of CR. 8 cases PR, 52 NC. the rate of PR + NC being 63. 5%. Another 52 cases were treated with chemotherapy +JFK. with 11 cases of PR, 26 cases NC, the rate of PR + NC being 71. 2%. While 25 cases were treated by chemotherapy alone, the cases of PR was 4; NC 26. the rate of PR + NC being 60. 0%, This demonstrated that the effect of JFK and JFK + chemotherapy were all superior to effect of chemotherapy alone. For 1 - and 2 - year survival rates, the JFK group was 67. 3% and 66. 7% respectively, whereas that of JFK + chemotherapy. 67. 3% and 66. 7%. For the chemotherapy group , 1 - year survival rate was 40. 3%, with no survivals within 2 years. For symptom improvement, body weight gaining, and health condition (KPS evaluation) after treatment, the JFK and JFK + chemotherapy groups were, again, superior to the chemotherapy group. The Immunity indices and blood picture in JFK group after treatment were markedly improved as compared with those before treatment, but, those in the chemotherapy group were decreased, while those of the JFK + chemotherapy group remained unchanged.